News Releases

View all Historical Press Releases

Investor Alerts

Oct 15, 2018

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma

Princeton, NJ – October 15, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 4, 2018

Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit

Princeton, NJ – October 4, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Sep 13, 2018

NIH selects Soligenix’s SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program

Princeton, NJ – September 13, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Sep 5, 2018

Soligenix to Present at BioCentury’s 25th Annual NewsMakers in the Biotech Industry

Princeton, NJ – September 5, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Sep 4, 2018

Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine

Princeton, NJ – September 4, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

Show per page